Rapidly progressive dementia (RPD) is an umbrella term covering many devastating conditions, including Creutzfeldt-Jakob disease (CJD). In this test-specific episode of the "Answers From the Lab" podcast, Gregg Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test guide diagnosis, prognosis, and treatment decisions.

"The biggest challenge we face when we see a patient with rapidly progressive dementia is, what is the cause?" Dr. Days says. "Ordering the RPD panel — which includes Alzheimer's disease biomarkers, CJD-specific markers, and combinations of those ratios that can help discriminate between those two — is a really good start."

The RPD panel is especially appropriate for dementia cases that have faster onset than Alzheimer's disease but don't appear to be typical CJD. "The CJD panel can be ordered alone if clinicians are confident a patient meets the criteria for possible or probable CJD," Dr. Day says.

For patients with suspected autoimmune dementia, Mayo Clinic Laboratories offers testing in serum (Mayo ID: DMS2) and cerebrospinal fluid (Mayo ID: DMC2). "That's another very important set of tests to consider for patients with rapidly progressive dementia," Dr. Day says.

Listen to learn more about Mayo Clinic Laboratories' RPD and CJD evaluations.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

RPDE    | Rapidly Progressive Dementia Evaluation, Spinal Fluid

CJDE    | Creutzfeldt-Jakob Disease Evaluation, Spinal Fluid

The latest

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

June 11, 2024

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.

June 4, 2024

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

May 14, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

View MoreView Less